Atrasentan in Patients With IgA Nephropathy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.
Epistemonikos ID: d876ef34f9964085e41676952f9ebecc265f0085
First added on: May 07, 2024